According to RationalStat Analysis, the Global Biologics Outsourcing Market is expected to reach a market value of US$ 70 billion by the end of 2028


Posted December 1, 2022 by kimberlyshaw

The market for outsourcing biologics is anticipated to grow at a rate of 12.5 percent over the period 2022-2028.

 
The report entitled "Biologics Outsourcing Market" assesses the market in both regional and global terms according to the type of product, the application, source, end use, and region. A thorough report offers thorough historical and forecast market size and trends analysis. The report focuses on a breakdown of the market's share, the overview of competition strategic imperatives, annual revenue outsourcing options market developments, growth avenues, markets forecasts, trends, and a competitive assessment of the players that are targeted in the study on outsourcing for biologics.
Market overview and dynamics Demand for the outsourcing of biologics is expected to increase during the forecast time because of the growing biologics sector.
The market for outsourcing biologics is anticipated to grow at a rate of 12.5 percent over the period 2022-2028. The biologics industry is rapidly growing across the globe is expected to help in the expansion of the global outsourcing market for biologics over the forecast time.
The global market for biologics is predicted to experience a rapid expansion over the coming six years. The increasing use of advanced technology for the production of biological products, increasing outsourcing of R&D by pharmaceutical and biopharmaceutical companies as well as favourable regulatory conditions to conduct clinical studies are just a few of the major factors which are likely to boost outsourcing of biologics around the world.
North America is expected to be the dominant player in the global market for outsourcing biologics. Developed regions like North America and Europe are likely to enjoy a large part of the worldwide outsourcing market for biologics because of the government's support and the increased use of modern technology in the field of healthcare. Asia Pacific biologics outsourcing market is anticipated to expand significantly due to the rise in non-communicable diseases and the increasing demand for biologics. This directly affects the market for outsourcing regional biologics positively.
Segmental Analysis
• Based on the kind of product the monoclonal antibody market increased significantly due to its superior specificity and high reliability in the past few years.
• Based on their application stem cell therapy, it is predicted to expand significantly over the next few years due to the growing demand to use iPSCs in lieu of ESCs.
• Based on regions, North America is the most populated region, due to an increase in awareness of the use of biologics and a rise in investment in research and development in the region.

Competition Analysis
The global biologics outsourcing market is fragmented in nature with the presence of various players operating in the region. Government and private players are focusing on growing R&D for the growth of the market. These players adopt various strategies in order to reinforce the demand for biologics outsourcing. Mergers and acquisitions, partnerships and collaborations, and product launches are some of the strategies followed by industry players. Some of the key developments in the global condensing units market include,
• In April 2022, FUJIFILM Diosynth Biotechnologies (FUJIFILM Corp.) completed the acquisition of Atara Biotherapeutics Inc.’s dedicated cell therapy manufacturing facility. FUJIFILM seeks to manufacture cell therapies for other companies in addition to Atara by using this facility.
• In January 2022, Samsung Biologics agreed to pay US$ 2.3 billion for Biogen’s 50% stake in Samsung Bioepis, a joint venture between the two companies. This is aimed to improve Samsung Bioepis’ biosimilar development capabilities and future performance in new drug development.
Some of the prominent players operating in the market include Lonza Group AG, Wuxi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Abzena Limited, GL Biochem Corp., Catalent Inc., Samsung Biologics Co. Ltd., ThermoFisher Scientific Inc., Syngene International Ltd., Rentschler Biopharma SE, Abbvie Inc. and Genescript Biotech Corp., among others.
RationalStat has segmented the global biologics outsourcing market on the basis of product type, source, application, end use, and region.
• By Product Type
o Antibodies
 Monoclonal Antibody
 Antibody Drug Conjugates
 Others (Polyclonal Antibodies etc.)
o Recombinant Proteins
o Vaccines
o Others (Fusion Proteins, etc.)
• By Source
o Human
o Microbial
o Others (Transgenic Animals such as Avian, Insects, etc.)
• By Application
o Stem Cell Research
o Vaccine and Therapeutics Development
o Blood & Blood-Related Products Development
o Cellular and Gene Therapy Products Development
o Others (Tissue & Tissue Related Products Development)
• By End Use
o Therapeutics and Diagnostics
o Research
• By Region
o North America
 US
 Canada
o Latin America
 Brazil
 Mexico
 Rest of Latin America
o Western Europe
 Germany
 UK
 France
 Spain
 Italy
 Benelux
 Nordic
 Rest of Western Europe
o Eastern Europe
 Russia
 Poland
 Rest of Eastern Europe
o Asia Pacific
 China
 Japan
 India
 South Korea
 Australia
 ASEAN (Indonesia, Vietnam, Malaysia, etc.)
 Rest of Asia Pacific
o Middle East & Africa
 GCC
 South Africa
 Turkey
 Rest of the Middle East & Africa
For more information about this report visit https://store.rationalstat.com/store/growth-opportunity-analysis-global-biologics-outsourcing-market/
About RationalStat LLC
RationalStat is an end-to-end US-based market intelligence and consulting company that provides comprehensive market research reports along with customized strategy and consulting studies. The company has sales offices in India, Mexico, and the US to support global and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.
RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the clients’ needs. Additional services offered by the company include consumer research, country reports, risk reports, procurement intelligence, data analytics, and analytical dashboards.
Contact
RationalStat LLC
Kimberly Shaw, Content and Press Manager
[email protected]
Phone: +1 302 803 5429
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By RationalStat
Phone 3028035429
Business Address 2055 Limestone Rd STE 200-C, Wilmington, DE 19808, USA
Country United States
Categories Health
Tags global opportunity analysis
Last Updated December 1, 2022